Unknown PHASE1 INTERVENTIONAL 2-arm NCT04175158

Clinical Trial in Chinese Healthy Volunteers of GB222

A Randomized, Double-blind, Parallel-controlled Comparative Study to Evaluate the PK Pharmacokinetic Similarity After Single Administration of GB222 and Bevacizumab in Healthy Volunteers.

Sponsor: Genor Biopharma Co., Ltd.

Conditions Non-small Cell Lung Cancer

Interventions Bevacizumab GB222

Updated 5 times since 2019 Last updated: Nov 21, 2019 Started: Apr 24, 2017 Primary completion: Aug 31, 2020 Completion: Nov 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Non-small Cell Lung Cancer, this trial is ongoing. The trial is conducted by Genor Biopharma Co., Ltd. and has accumulated 5 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Dec 2019 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Apr 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genor Biopharma Co., Ltd.

Data source: Genor Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China